Evoke Pharma, Inc. Selects SynteractHCR As Contract Research Organization For Phase 3 Trial Of EVK-001 For Gastroparesis

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of SynteractHCR, Inc. to serve as its primary contract research organization ("CRO") for its upcoming Phase 3 clinical trial of EVK-001. EVK-001 is a novel metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Selection of SynteractHCR follows the successful completion of Evoke's 287 patient, multi-center Phase 2b clinical trial of EVK-001, for which SynteractHCR was the primary CRO.

Help employers find you! Check out all the jobs and post your resume.

Back to news